In systemic lupus erythematosus (SLE) trials, the placebo arm is never truly placebo; it reflects the clinical reality of background therapy distorting the signal. High placebo rates in lupus trials continue to be a major obstacle to detecting the statistical incremental value of an investigational product (IP).
Enrolled patients randomized to placebo are virtually always being simultaneously treated with an established, potent background therapy, whether the standard of care (SOC) is glucocorticoids, hydroxychloroquine or an immunosuppressant like mycophenolate or azathioprine. These are not inert comparators; they are active medications that can meaningfully reduce disease activity on their own; improvements that register as responses on composite responder indices (e.g., SRI-4).
To complicate things further, SLE patients of either randomization arm frequently enter trials with active disease and then receive prompt initiation or intensification of SOC therapy. Even when trial protocols attempt to standardize background therapy, real-world variability persists across sites, geographies, and investigators, introducing additional noise. Polypharmacy within a clinical trial is unavoidable, of course; effective therapies cannot ethically be withdrawn from patients with an unpredictable, potentially organ-threatening disease such as SLE.
From EXPLORER to pooled analysis: Persistently high placebo rate
In the EXPLORER trial, which enrolled patients with moderately-to-severely active SLE and used aggressive background treatment and sensitive cutoffs for nonresponse, no differences were noted between placebo and rituximab in the primary and secondary endpoints. That trial was certainly not an isolated case; overall placebo response in lupus trials has been measured and found to be high. A pooled analysis of 24 randomized clinical trials of non-renal, non-neuropsychiatric SLE showed that approximately 40% of placebo plus SOC patients reached SRI-4 response by week 48 to 52.
Derailing drug development
The structural challenge of signal distortion continues to frustrate drug development in lupus, resulting in cases such as:
- A biologic with genuine clinical activity may fail to separate from placebo.
- A trial may be interpreted as negative, despite meaningful therapeutic effect.
- Investment decisions may be made on incomplete or misleading evidence.
These types of devastating scenarios are all too familiar in late-stage trials of various promising agents in SLE, not necessarily because they lacked efficacy, but because the comparator arm performed too well. In effect, the IP inadvertently ends up being tested against a multi-drug therapeutic platform that already delivers clinical benefit.
Strategies to answer the true question
Rather than âdoes this IP work?â in SLE trials, the true question being asked is: âOn top of an already effective regimen, does the new drug add enough to produce a detectable incremental signal?â Trial design and conduct strategies can help answer that question:
- Stabilize the background: Standardizing and stabilizing concomitant medications reduces variability and limits artificial inflation of placebo responses.
- Evaluate adaptive features: Lupus trials that include innovations like dose-finding with response-adaptive randomization and Bayesian adaptive design are increasingly accepted by regulators (e.g.,FDAâs Complex Innovative Trial Design pilot).
- Power studies sufficiently: Recent pivotal trials enroll 400 to 800 patients to ensure that, even with a strong placebo arm, the study retains 90% power. (Consider site backup plans.)
- Refine endpoints: There is growing emphasis on sustained responses, rather than point-in-time assessments, organ-specific outcomes and steroid-sparing effects, as clinically meaningful endpoints. In SLE, different organ systems respond differently to therapy, and failure to meet the primary endpoint does not necessarily mean the molecule failed. It could be the study designâs failure to isolate the drugâs contribution.
- Optimize steroid use: Structured tapering protocols, and limiting steroid bursts, help ensure that observed improvements are attributable to the investigational agent rather than rescue therapy.
- Have operational rigor: Establish expert, central review at entry gate and ongoing. For example, protocol deviations (i.e. rescue meds not reported) are caught before they inflate the placebo arm.
- Enrich study populations: Selecting patients with higher disease activity or specific biological characteristics can amplify the ability to detect treatment effects.
- Include patient reported outcomes (PROs) and refine outcome instruments to capture meaningful change that may be missed by composite indices.
- Dial back âwhite-coat therapyâ: Since monthly clinic visits can contribute to placebo, consider reducing the frequency of routine in-person visits (e.g., to every 2-3 months) while retaining essential lab monitoring.
Modest but consistent improvement
Even successful lupus therapies do not produce dramatic, immediate transformations. Approved biologics, such as belimumab and anifrolumab, demonstrate modest but consistent improvements layered onto standard care.
Sponsors are advised to lock steroid policies in the protocol, link mechanism with phenotype, and pre-specify an endpoint that is placebo-resistant and acceptable to regulators.
Rather than trying to outperform placebo in a vacuum, sponsors should aim to demonstrate reliable, additive benefit in a highly treated population. After all, every lupus IP deserves a fair chance to show its true added value, without SOC noise hiding the signal.
Enjoying your read? Continue the conversation at Indero’s breakfast event at the ACR Convergence 2026.
About the author
Dr. Juan Ovalles, MD, PhD, is Senior Medical Director of Rheumatology at Indero, providing medical leadership and strategic guidance in rheumatology research. He collaborates with business development, supports operational and regulatory teams, and builds relationships with key stakeholders. With more than 14 years of clinical development experience, Dr. Ovalles began his career as an investigator in 2012 and transitioned to the CRO industry in 2021. A board-certified rheumatologist with a PhD in biomedical sciences, he specializes in innovative therapies for immune-mediated, inflammatory diseases.
